CoChat

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature

Open access
Alvarez-Twose, Iván, Matito, Almudena, Morgado, José Mário, Sánchez-Muñoz, Laura, Jara-Acevedo, María, García-Montero, Andrés, Mayado, Andrea, Caldas, Carolina, Teodósio, Cristina, Muñoz-González, Javier Ignacio, Mollejo, Manuela, Escribano, Luis, Orfao, Alberto · 2017 · Oncotarget
Cited by 102

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

// Iván Alvarez-Twose 1, 5 , Almudena Matito 1, 5 , José Mário Morgado 1, 5 , Laura Sánchez-Muñoz 1, 5 , María Jara-Acevedo 2, 5 , Andrés García-Montero 2, 5 , Andrea Mayado 2, 5 , Carolina Caldas 2, 5 , Cristina Teodósio 3 , Javier Ignacio Muñoz-González 2, 5 , Manuela Mollejo 4, 5 , Luis Escribano 2, 5 and Alberto Orfao 2, 5 1 Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain 2 Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría, University of Salamanca, Salamanca, Spain 3 Department of Immunology, Erasmus Medical Center, University of Rotterdam, Rotterdam, The Netherlands 4 Department of Pathology, Hospital Virgen de la Salud, Toledo, Spain 5 Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain Correspondence to: Iván Alvarez-Twose, email: ivana@sescam.jccm.es Keywords: mast cell, mastocytosis, well-differentiated systemic mastocytosis, imatinib, KIT Received: March 01, 2016 Accepted: May 29, 2016 Published: July 19, 2016 ABSTRACT Resistance to imatinib has been recurrently reported in systemic mastocytosis (SM) carrying exon 17 KIT mutations. We evaluated the efficacy and safety of imatinib therapy in 10 adult SM patients lacking exon 17 KIT mutations, 9 of which fulfilled criteria for well-differentiated SM (WDSM). The World Health Organization 2008 disease categories among WDSM patients were mast cell (MC) leukemia ( n = 3), indolent SM ( n = 3) and cutaneous mastocytosis ( n = 3); the remainder case had SM associated with a clonal haematological non-MC disease. Patients were given imatinib for 12 months –400 or 300 mg daily depending on the presence vs. absence of > 30% bone marrow (BM) MCs and/or signs of advanced disease–. Absence of exon 17 KIT mutations was confirmed in highly-purified BM MCs by peptide nucleic acid-mediated PCR, while mutations involving other exons were investigated by direct sequencing of purified BM MC DNA. Complete response (CR) was defined as resolution of BM MC infiltration, skin lesions, organomegalies and MC-mediator release-associated symptoms, plus normalization of serum tryptase. Criteria for partial response (PR) included ≥ 50% reduction in BM MC infiltration and improvement of skin lesions and/or organomegalies. Treatment was well-tolerated with an overall response rate of 50%, including early and sustained CR in four patients, three of whom had extracellular mutations of KIT , and PR in one case. This later patient and all non-responders ( n = 5) showed wild-type KIT . These results together with previous data from the literature support the relevance of the KIT mutational status in selecting SM patients who are candidates for imatinib therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.10711

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 102

Metadata

Authors
Alvarez-Twose, I., Matito, A., Morgado, J. M., Sánchez-Muñoz, L., Jara-Acevedo, M., García-Montero, A., Mayado, A., Caldas, C., Teodósio, C., Muñoz-González, J. I., Mollejo, M., Escribano, L., & Orfao, A.
Venue
Oncotarget
Published
2016-07-19
Volume
8
Issue
40
Pages
68950-68963
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2485655499
Cited by
102
References
5
FWCI
4.21
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. https://app.cochat.ai/papers/10.18632/oncotarget.10711
The paper
Alvarez-Twose, I., Matito, A., Morgado, J. M., Sánchez-Muñoz, L., Jara-Acevedo, M., García-Montero, A., Mayado, A., Caldas, C., Teodósio, C., Muñoz-González, J. I., Mollejo, M., Escribano, L., & Orfao, A. (2017). Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget. https://doi.org/10.18632/oncotarget.10711

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.